Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor – A Meta-analysis originally posted on the JAMA Network Importance  Current guidelines recommend both epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic chemotherapy drugs as standard treatment options for patients… Read More »

Blockbuster drug Nexavar fails a liver cancer test The blockbuster cancer drug Nexavar, co-developed by South San Francisco’s Onyx Pharmaceuticals Inc., failed a late-stage clinical trial in a subset of liver cancer patients. Onyx, a subsidiary of Amgen Inc. (NASDAQ: AMGN) since a $10.5 billion buyout in October, and partner Bayer HealthCare Pharmaceuticals Inc. said… Read More »

Susana Campos, MD, MPH reviewing Tewari KS et al. N Engl J Med 2014 Feb 20. Adding bevacizumab to chemotherapy significantly improved overall survival. Several cytotoxic regimens are often employed in the management of patients with advanced cervical cancer. Regrettably, advanced cervical cancer does not have a sustained response to chemotherapy. Bevacizumab has single-agent activity in heavily pretreated, recurrent… Read More »

Council of Surgical Spine Societies to Aetna: Cages for Cervical Spinal Fusion Not Investigational   Written by  Laura Miller | Friday, 10 January 2014 11:50   The Council of Surgical Spine Societies recently penned a letter to Aetna commenting on the insurer’s back pain and invasive procedures policy. The letter was sent in December 2013 for the Jan. 9,… Read More »

Advanced Medical Strategies experiences rapid subscriber growth for PredictDx   PredictDx gives Health Care Payors, Carriers and Reinsurers unprecedented web access to clinical and financial details of 150+ diagnoses Advanced Medical Strategies has changed the way carriers, reinsurers, MGU’s, TPA’s, and Brokers predict and manage costs associated with trigger diagnoses. Advanced Medical Strategies’ PredictDx is… Read More »

Don’t miss a thing. AMS claims audits are performed by experienced professionals that ensure the completeness and accuracy of every claim before adjudication.

Gaining a clinical perspective means gaining possibilities, comprehension, and strategy. Without a clinical overview, there are missed opportunities to reach the best outcome. AMS physician-led reviews and reporting give you a fuller picture of how treatments relate to costs.

Find savings strategies for Bill Audits, Negotiations, and Reference based Pricing. AMS offers their complete services to find where your claims costs can be reduced.

AMS puts a “Physician in your pocket” with a digital library of clinically reviewed treatments or pharmaceuticals. Find and compare costs, treatment details, and risk analyses by using these searchable applications.

  United Therapeutics announced that the FDA has approved Orenitram (treprostinil) extended-release tablets for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. RELATED: Cardiovascular Disease Resource Center The approval was based on data from FREEDOM-M, the primary efficacy study that included patients with WHO functional class II to III symptoms… Read More »